Patients' interests: paramount in randomised trials

BMJ 2004; 330 doi: https://doi.org/10.1136/bmj.330.7481.44-a (Published 30 December 2004) Cite this as: BMJ 2004;330:44
  1. Tony Stevens, consumer liaison lead (t.stevens@ncrn.org.uk),
  2. Roger Wilson, chair, National Cancer Research Institute Consumer Liaison Group
  1. National Cancer Research Network, Cookridge Hospital, Leeds LS16 6QB

EDITOR—Patients and the public recognise the need for large randomised trials. Trialists must also recognise the responsibilities they owe to their study participants. There has been some debate on whether these responsibilities are always fully discharged.

The early stopping of the MA17 trial, with data released to the …

View Full Text

Log in

Log in through your institution


* For online subscription